RANDOMIZED CLINICAL-TRIAL OF 2 TREATMENT REGIMENS OF NATURAL SURFACTANT PREPARATIONS IN NEONATAL RESPIRATORY-DISTRESS-SYNDROME

被引:97
作者
SPEER, CP
GEFELLER, O
GRONECK, P
LAUFKOTTER, E
ROLL, C
HANSSLER, L
HARMS, K
HERTING, E
BOENISCH, H
WINDELER, J
ROBERTSON, B
机构
[1] UNIV GOTTINGEN, DEPT PAEDIAT, GOTTINGEN, GERMANY
[2] STADT KRANKENHAUS COLOGNE, DEPT MED STAT, COLOGNE, GERMANY
[3] STADT KRANKENHAUS COLOGNE, DEPT PAEDIAT, COLOGNE, GERMANY
[4] RUHR UNIV BOCHUM, DEPT PAEDIAT, BOCHUM, GERMANY
[5] UNIV ESSEN GESAMTHSCH, DEPT PAEDIAT, ESSEN, GERMANY
[6] STADT KRANKENHAUS BRAUNSCHWEIG, BRAUNSCHWEIG, GERMANY
[7] RUHR UNIV BOCHUM, DEPT MED INFORMAT & BIOMATH, BOCHUM, GERMANY
[8] KAROLINSKA INST, KAROLINSKA HOSP, RES UNIT EXPTL PERINATAL PATHOL, S-10401 STOCKHOLM, SWEDEN
来源
ARCHIVES OF DISEASE IN CHILDHOOD-FETAL AND NEONATAL EDITION | 1995年 / 72卷 / 01期
关键词
SURFACTANT TREATMENT; RESPIRATORY DISTRESS SYNDROME; CUROSURF; SURVANTA;
D O I
10.1136/fn.72.1.F8
中图分类号
R72 [儿科学];
学科分类号
100202 ;
摘要
Aims-To compare treatment regimens of two widely used natural surfactant preparations Curosurf and Survanta in respiratory distress syndrome (RDS). Methods-The effects of the two treatment regimens on gas exchange, ventilatory requirements, and 28 day outcome in infants with RDS were compared. Seventy fire preterm infants (birth weight 700-1500 g) with RDS requiring artificial ventilation with an FIO2 of greater than or equal to 0.4, were randomly selected at 1-24 hours of age. One group received an initial dose of Curosurf (200 mg/kg); the other group Survanta (100 mg/kg). Patients who remained dependent on artificial ventilation with an FIO2 of greater than or equal to 0.3 received up to two additional doses of Curosurf (each of 100 mg/kg) after 12 and 24 hours or up to three additional doses of Survanta (each of 100 mg/kg) between six and 48 hours after the initial dose. Results-There was a rapid improvement in oxygenation and ventilatory requirements were reduced in both groups. However, infants treated with Curosurf had a higher arterial:alveolar oxygen tension ratio and required a lower peak inspiratory pressure and mean airway pressure at several time points within 24 hours of randomisation (p<0.05-0.001). The incidences of pneumothorax in the Curosurf and Survanta groups were 6% and 12.5%, respectively; the corresponding figures for grades 3-4 intracerebral haemorrhage were 3% and 12.5%, respectively. Mortality was 3% in the Curosurf group and 12.5% in the Survanta group. However, these differences did not reach significance. Conclusion-The Curosurf treatment regimen resulted in a more rapid improvement in oxygenation than Survanta and reduced ventilatory requirements up to 24 hours aft er start of treatment. This was associated with a trend towards reduced incidence of serious pulmonary and nonpulmonary complications.
引用
收藏
页码:F8 / F13
页数:6
相关论文
共 50 条
  • [31] A multicenter, randomized, double-blind trial of a new porcine surfactant in premature infants with respiratory distress syndrome
    Rebello, Celso Moura
    Precioso, Alexander Roberto
    Mascaretti, Renata Suman
    EINSTEIN-SAO PAULO, 2014, 12 (04): : 397 - 404
  • [32] Clinical effects of pulmonary surfactant in combination with nasal continuous positive airway pressure therapy on neonatal respiratory distress syndrome
    Zhang, Congmin
    Zhu, Xiaojing
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2017, 33 (03) : 621 - 625
  • [33] Nasal intermittent positive pressure ventilation after surfactant treatment for respiratory distress syndrome in preterm infants <30 weeks’ gestation: a randomized, controlled trial
    R Ramanathan
    K C Sekar
    M Rasmussen
    J Bhatia
    R F Soll
    Journal of Perinatology, 2012, 32 : 336 - 343
  • [34] A Randomized, Controlled Trial of Poractant Alfa versus Beractant in the Treatment of Preterm Infants with Respiratory Distress Syndrome
    Dizdar, Evrim Alyamac
    Sari, Fatma Nur
    Aydemir, Cumhur
    Oguz, Serife Suna
    Erdeve, Omer
    Uras, Nurdan
    Dilmen, Ugur
    AMERICAN JOURNAL OF PERINATOLOGY, 2012, 29 (02) : 95 - 100
  • [35] Comparative trial of artificial and natural surfactants in the treatment of respiratory distress syndrome of prematurity: Experiences in a developing country
    da Costa, DE
    Pai, MGK
    Al Khusaiby, SM
    PEDIATRIC PULMONOLOGY, 1999, 27 (05) : 312 - 317
  • [36] A 2-YEAR FOLLOW-UP OF BABIES ENROLLED IN A EUROPEAN MULTICENTER TRIAL OF PORCINE SURFACTANT REPLACEMENT FOR SEVERE NEONATAL RESPIRATORY-DISTRESS SYNDROME
    ROBERTSON, B
    CURSTEDT, T
    TUBMAN, R
    STRAYER, D
    BERGGREN, P
    KOK, J
    KOPPE, J
    VANSONDEREN, L
    HALLIDAY, H
    MCCLURE, G
    REID, M
    OETEMO, SB
    OKKEN, A
    SPEER, C
    SCHROTER, W
    SVENNINGSEN, N
    WALTI, H
    RELIER, JP
    EUROPEAN JOURNAL OF PEDIATRICS, 1992, 151 (05) : 372 - 376
  • [37] Nasal intermittent positive pressure ventilation after surfactant treatment for respiratory distress syndrome in preterm infants &lt;30 weeks' gestation: a randomized, controlled trial
    Ramanathan, R.
    Sekar, K. C.
    Rasmussen, M.
    Bhatia, J.
    Soll, R. F.
    JOURNAL OF PERINATOLOGY, 2012, 32 (05) : 336 - 343
  • [38] Less Invasive Surfactant Administration (LISA) vs. Intubation Surfactant Extubation (InSurE) in Preterm Infants with Respiratory Distress Syndrome: A Pilot Randomized Controlled Trial
    Pareek, Prince
    Deshpande, Sujata
    Suryawanshi, Pradeep
    Sah, Love Kumar
    Chetan, Chinmay
    Maheshwari, Rajesh
    More, Kiran
    JOURNAL OF TROPICAL PEDIATRICS, 2021, 67 (04)
  • [39] Aerosolized Beractant in neonatal respiratory distress syndrome: A randomized fixed-dose parallel-arm phase II trial
    Sood, Beena G.
    Thomas, Ronald
    Delaney-Black, Virginia
    Xin, Yuemin
    Sharma, Amit
    Chen, Xinguang
    PULMONARY PHARMACOLOGY & THERAPEUTICS, 2021, 66
  • [40] The impact of combined administration of surfactant and intratracheal budesonide compared to surfactant alone on bronchopulmonary dysplasia (BPD) and mortality rate in preterm infants with respiratory distress syndrome: a single-blind randomized clinical trial
    Marzban, Asghar
    Mokhtari, Samira
    Tavakkolian, Pouria
    Mansouri, Reza
    Jafari, Nahid
    Maleki, Azam
    BMC PEDIATRICS, 2024, 24 (01)